To include your compound in the COVID-19 Resource Center, submit it here.

Alnylam, Tekmira deal

Tekmira received rights from Alnylam to develop RNAi therapeutic targeting

Read the full 101 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE